<DOC>
	<DOCNO>NCT01941095</DOCNO>
	<brief_summary>This multicenter , open-label , single arm study evaluate safety efficacy subcutaneous ( SC ) tocilizumab monotherapy combination methotrexate non-biologic DMARDs participant active rheumatoid arthritis either naïve inadequate response prior non-biologic or/and biologic DMARDs . The anticipated time study treatment 52 week . Those participant complete 60-week study period achieve Disease Activity Score ( DAS ) 28 remission good European League Against Rheumatism ( EULAR ) response 52 week eligible enter extension phase tocilizumab commercially available reimburse Greece .</brief_summary>
	<brief_title>A Study Subcutaneous Tocilizumab Monotherapy and/or Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs ( DMARDs ) Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Diagnosis active rheumatoid arthritis accord revise ( 1987 ) ACR criterion EULAR/ACR ( 2010 ) criterion Oral corticosteroid ( less equal [ &lt; /= ] 10 milligram per day [ mg/day ] prednisolone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ; maximum recommend dose ) permit stable dose regimen great equal [ &gt; /= ] 4 week prior baseline Permitted non biologic DMARDs allow stable dose least 4 week prior baseline Receiving treatment outpatient basis , include tocilizumab Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception study ; female childbearing potential must use reliable mean contraception least 3 month follow last dose tocilizumab Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline Rheumatic autoimmune disease rheumatoid arthritis ; secondary Sjögren 's syndrome rheumatoid arthritis permit Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile rheumatoid arthritis and/or rheumatoid arthritis age 16 Prior history current inflammatory joint disease rheumatoid arthritis Participants lack peripheral venous access Exposure tocilizumab ( either intravenous [ IV ] SC ) time prior baseline Treatment investigational agent within 4 week ( five halflives investigational drug , whichever long ) screen Previous treatment celldepending therapy Treatment IV gamma globulin , plasmapheresis within 6 month baseline Intraarticular parenteral corticosteroid within 4 week prior baseline Immunization live/attenuated vaccine within 4 week prior baseline Any previous treatment alkylating agent chlorambucil , total lymphoid irradiation History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) , gastrointestinal disease Known active current history recurrent bacterial , viral , fungal , mycobacterial , infection Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week screen Active Tuberculosis ( TB ) require treatment within previous 3 year Positive hepatitis B surface antigen hepatitis C antibody Primary secondary immunodeficiency ( history currently active ) Evidence active malignant disease , malignancy diagnose within previous 10 year ( except basal squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) , breast cancer diagnose within previous 20 year Pregnancy breast feeding woman History alcohol , drug chemical abuse within 1 year prior screen Neuropathies condition interfere pain evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>